One global company innovating for millions. Covance is now Labcorp Drug Development.

Moving ahead, Covance will be known as Labcorp Drug Development—reflecting years of shared pursuit with Labcorp delivering health breakthroughs. With unmatched global

scale, scientific expertise and virtual clinical trial capabilities, we are determined to keep pushing forward to help bring cutting-edge treatments to patients everywhere.

Go to article: Home | Time for UK plasma to shineGo to article: In this issueGo to article: ContentsGo to article: DatwylerGo to article: LabcorpGo to article: UPS Healthcare Company InsightGo to article: UPS Healthcare Go to article: BaxterGo to article: SHL MedicalGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: PerkinElmerGo to article: CommentGo to article: A new day for Alzheimer’s disease treatmentGo to article: Covid-19 vaccine inequity: the debate over patent waivers intensifiesGo to article: Covid-19 vaccines show efficacy in adolescentsGo to article: International pharmacovigilance for biotechs: forming a strategyGo to article: NiproGo to article: HOF SonderanlagenbauGo to article: MyonexGo to article: In DepthGo to article: Malaria vaccines through the agesGo to article: Are competition authorities tightening the rules on pharma M&A? Go to article: The fishy business of shark squaleneGo to article: Without a trace: can pharma reduce scarring?Go to article: Blood plasma production: OK for the UK?Go to article: When the drugs don’t work: can pharma keep up with mental health?Go to article: The Solubility Company - Company Insight Go to article: The Solubility companyGo to article: Owen Mumford Company InsightGo to article: Owen MumfordGo to article: In DataGo to article: Deals analysisGo to article: The pharma industry key listGo to article: Global markets and indicesGo to article:  Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: EventsGo to article: Next issue